Strategic investors hold at least a million shares. I wonder if the petition to not disclose info made to the SEC has to do with hiding the name of the strategic owner of those shares. If it is a big pharma it would set off a bidding war sooner than later and drive up the cost for either a partnership or an acquisition. I also wonder if the strategic now exceeds the 5% threshold of ownership for this same disclosure which would trigger a mandatory SEC filing.
strategic investors hold nearly ALL of the shares.
the facts (shareholder and this CT-order) are all at the SEC website for all to see/read:
the redactions are simply and only related to the particulars of the Therapure contract manufacturing agreement: batch size, batch costs, payment terms, capital equipment costs (who will pay how much and when), forecasts, delivery obligations, liabilities, etc. Nothing more, nothing less.
How do we know what has been redacted? Typically those types of things are not required to be stated or disclosed in filings. Coca Cola doesn't have to post their formula, bottler relationships, cost structure, customers, etc. Nor does anyone else. They do have to report shareholder activity at certain thresholds though.
Roche went shopping for US biotech. The Swiss drugmaker will pay up to $1.7 billion for privately-held US-based Seragon, which specializes in breast cancer treatments—$725 million in cash, and up to $1 billion more if Seragon achieves some development milestones.